CoChat

Myostatin – The Holy Grail for Muscle, Bone, and Fat?

Buehring, B., Binkley, N. · 2013 · Current Osteoporosis Reports

The DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index.

Abstract

Myostatin, a member of the transforming growth factor beta (TGF-β) superfamily, was first described in 1997. Since then, myostatin has gained growing attention because of the discovery that myostatin inhibition leads to muscle mass accrual. Myostatin not only plays a key role in muscle homeostasis, but also affects fat and bone. This review will focus on the impact of myostatin and its inhibition on muscle mass/function, adipose tissue and bone density/geometry in humans. Although existing data are sparse, myostatin inhibition leads to increased lean mass and 1 study found a decrease in fat mass and increase in bone formation. In addition, myostatin levels are increased in sarcopenia, cachexia and bed rest whereas they are increased after resistance training, suggesting physiological regulatory of myostatin. Increased myostatin levels have also been found in obesity and levels decrease after weight loss from caloric restriction. Knowledge on the relationship of myostatin with bone is largely based on animal data where elevated myostatin levels lead to decreased BMD and myostatin inhibition improved BMD. In summary, myostatin appears to be a key factor in the integrated physiology of muscle, fat, and bone. It is unclear whether myostatin directly affects fat and bone, or indirectly via muscle. Whether via direct or indirect effects, myostatin inhibition appears to increase muscle and bone mass and decrease fat tissue-a combination that truly appears to be a holy grail. However, at this time, human data for both efficacy and safety are extremely limited. Moreover, whether increased muscle mass also leads to improved function remains to be determined. Ultimately potential beneficial effects of myostatin inhibition will need to be determined based on hard outcomes such as falls and fractures.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11914-013-0160-5

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 83 references

Cited by

See all 79

Metadata

Authors
Buehring, B., & Binkley, N.
Affiliations
University of Wisconsin–Madison (US)
Corresponding author
Buehring, B.
Venue
Current Osteoporosis Reports
Published
2013-09-27
Volume
11
Issue
4
Pages
407-414
ISSN
  • 1544-1873 (ISSN-L)
  • 1544-2241
OpenAlex
W2008990345
Cited by
79
References
84
Citations by year
2026: 4 · 2025: 5 · 2024: 8 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 8 · 2018: 6 · 2017: 11 · 2016: 2 · 2015: 5 · 2014: 10
FWCI
0.53
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Current Osteoporosis Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
myostatin, myostatin inhibition, muscle mass, muscle function, bone mineral density, bone geometry, adipose tissue, fat mass, lean body mass, sarcopenia, cachexia, resistance training, obesity, caloric restriction, TGF-beta superfamily
MeSH terms
Adipose Tissue, Animals, Bone and Bones, Humans, Muscles, Obesity, Osteoporosis, Signal Transduction, Myostatin, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Myostatin – The Holy Grail for Muscle, Bone, and Fat? https://app.cochat.ai/papers/10.1007/s11914-013-0160-5
The paper
Buehring, B., & Binkley, N. (2013). Myostatin – The Holy Grail for Muscle, Bone, and Fat? Current Osteoporosis Reports. https://doi.org/10.1007/s11914-013-0160-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.